Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.

Purpose To compare fluorine 18 ((18)F) fluorodeoxyglucose (FDG) combined positron emission tomography (PET) and magnetic resonance (MR) imaging with (18)F FDG combined PET and computed tomography (CT) in terms of organ-specific metastatic lesion detection and radiation dose in patients with breast cancer. Materials and Methods From July 2012 to October 2013, this institutional review board-approved HIPAA-compliant prospective study included 51 patients with breast cancer (50 women; mean age, 56 years; range, 32-76 years; one man; aged 70 years) who completed PET/MR imaging with diffusion-weighted and contrast material-enhanced sequences after unenhanced PET/CT. Written informed consent for study participation was obtained. Two independent readers for each modality recorded site and number of lesions. Imaging and clinical follow-up, with consensus in two cases, served as the reference standard. Results There were 242 distant metastatic lesions in 30 patients, 18 breast cancers in 17 patients, and 19 positive axillary nodes in eight patients. On a per-patient basis, PET/MR imaging with diffusion-weighted and contrast-enhanced sequences depicted distant (30 of 30 [100%] for readers 1 and 2) and axillary (eight of eight [100%] for reader 1, seven of eight [88%] for reader 2) metastatic disease at rates similar to those of unenhanced PET/CT (distant metastatic disease: 28 of 29 [96%] for readers 3 and 4, P = .50; axillary metastatic disease: seven of eight [88%] for readers 3 and 4, P > .99) and outperformed PET/CT in the detection of breast cancer (17 of 17 [100%] for readers 1 and 2 vs 11 of 17 [65%] for reader 3 and 10 of 17 [59%] for reader 4; P < .001). PET/MR imaging showed increased sensitivity for liver (40 of 40 [100%] for reader 1 and 32 of 40 [80%] for reader 2 vs 30 of 40 [75%] for reader 3 and 28 of 40 [70%] for reader 4; P < .001) and bone (105 of 107 [98%] for reader 1 and 102 of 107 [95%] for reader 2 vs 106 of 107 [99%] for reader 3 and 93 of 107 [87%] for reader 4; P = .012) metastases and revealed brain metastases in five of 51 (10%) patients. PET/CT trended toward increased sensitivity for lung metastases (20 of 23 [87%] for reader 1 and 17 of 23 [74%] for reader 2 vs 23 of 23 [100%] for reader 3 and 22 of 23 [96%] for reader 4; P = .065). Dose reduction averaged 50% (P < .001). Conclusion In patients with breast cancer, PET/MR imaging may yield better sensitivity for liver and possibly bone metastases but not for pulmonary metastases, as compared with that attained with PET/CT, at about half the radiation dose. (©) RSNA, 2016 Online supplemental material is available for this article.

[1]  G. V. von Schulthess,et al.  Whole-body nonenhanced PET/MR versus PET/CT in the staging and restaging of cancers: preliminary observations. , 2014, Radiology.

[2]  R. Sievert,et al.  Book Reviews : Recommendations of the International Commission on Radiological Protection (as amended 1959 and revised 1962). I.C.R.P. Publication 6. 70 pp. PERGAMON PRESS. Oxford, London and New York, 1964. £1 5s. 0d. [TB/54] , 1964 .

[3]  D. Loeffelbein,et al.  Performance of Whole-Body Integrated 18F-FDG PET/MR in Comparison to PET/CT for Evaluation of Malignant Bone Lesions , 2014, The Journal of Nuclear Medicine.

[4]  M. Senda,et al.  Accuracy of whole-body FDG-PET/CT for detecting brain metastases from non-central nervous system tumors , 2008, Annals of nuclear medicine.

[5]  G. Brix,et al.  Radiation exposure of patients undergoing whole-body FDG-PET/CT examinations , 2014, Nuklearmedizin.

[6]  Martin G Mack,et al.  Colorectal carcinoma metastases in liver: laser-induced interstitial thermotherapy--local tumor control rate and survival data. , 2004, Radiology.

[7]  A. Loft,et al.  Contrast-enhanced FDG-PET/CT vs. spio-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation , 2007, Acta radiologica.

[8]  Thomas Beyer,et al.  Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  W. Huda,et al.  CT effective dose per dose length product using ICRP 103 weighting factors. , 2011, Medical physics.

[10]  Sebastian Fürst,et al.  PET/MR Imaging in the Detection and Characterization of Pulmonary Lesions: Technical and Diagnostic Evaluation in Comparison to PET/CT , 2014, The Journal of Nuclear Medicine.

[11]  C. Claussen,et al.  Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging--pilot study. , 2012, Radiology.

[12]  Willi A Kalender,et al.  The effect of angular and longitudinal tube current modulations on the estimation of organ and effective doses in x-ray computed tomography. , 2009, Medical physics.

[13]  W. Meyers,et al.  Liver metastases from breast cancer: long-term survival after curative resection. , 2000, Surgery.

[14]  Felix Nensa,et al.  Whole-body [18F]FDG PET/MRI vs. PET/CT in the assessment of bone lesions in oncological patients: initial results , 2014, European Radiology.

[15]  H. Chandarana,et al.  Outcome of small lung nodules missed on hybrid PET/MRI in patients with primary malignancy , 2016, Journal of magnetic resonance imaging : JMRI.

[16]  C. Mader,et al.  Discrimination and anatomical mapping of PET-positive lesions: comparison of CT attenuation-corrected PET images with coregistered MR and CT images in the abdomen , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  Pek-Lan Khong,et al.  Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. , 2009, Radiology.

[18]  Gerald Q. Maguire,et al.  Role of Fusion of Prone FDG‐PET and Magnetic Resonance Imaging of the Breasts in the Evaluation of Breast Cancer , 2010, The breast journal.

[19]  Sergios Gatidis,et al.  Simultaneous whole-body PET/MR imaging in comparison to PET/CT in pediatric oncology: initial results. , 2014, Radiology.

[20]  Felix Nensa,et al.  Diagnostic accuracy of whole-body PET/MRI and whole-body PET/CT for TNM staging in oncology , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  U. Schick,et al.  Breast cancer brain metastases - A 12 year review of treatment outcomes. , 2015, Breast.

[22]  B R Rosen,et al.  Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients , 2015, British Journal of Cancer.

[23]  M. Wyss,et al.  [18F]-fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer , 2003, Journal of Cancer Research and Clinical Oncology.

[24]  D. Groheux,et al.  Prognostic Impact of 18FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer , 2012, Journal of the National Cancer Institute.

[25]  Walter Huda,et al.  Converting dose-length product to effective dose at CT. , 2008, Radiology.

[26]  Y Maruyama,et al.  A randomized trial of surgery in the treatment of single metastases to the brain. , 1990, The New England journal of medicine.

[27]  J. Babb,et al.  Standardized Uptake Values from PET/MRI in Metastatic Breast Cancer: An Organ‐based Comparison With PET/CT , 2016, The breast journal.

[28]  M. Phelps,et al.  Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  A. Alavi,et al.  Clinicopathologic factors associated with false negative FDG–PET in primary breast cancer , 2006, Breast Cancer Research and Treatment.

[30]  A. Bleyer,et al.  Breast cancer before age 40 years. , 2009, Seminars in oncology.

[31]  M. J. Fusselman,et al.  Brain metastases from non-central nervous system tumors: evaluation with PET. , 1993, Radiology.

[32]  A. Drzezga,et al.  First Clinical Experience with Integrated Whole-Body PET/MR: Comparison to PET/CT in Patients with Oncologic Diagnoses , 2012, The Journal of Nuclear Medicine.

[33]  A. Jena,et al.  imultaneous whole-body 18 F-FDG PET-MRI in primary staging of reast cancer : A pilot study , 2014 .

[34]  Jack Valentin,et al.  The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. , 2007, Annals of the ICRP.

[35]  K. Eichler,et al.  Breast cancer metastases in liver: laser-induced interstitial thermotherapy--local tumor control rate and survival data. , 2004, Radiology.

[36]  Andrea Soricelli,et al.  Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues. , 2014, European journal of radiology.

[37]  I. Cho,et al.  Evaluation of Dixon Sequence on Hybrid PET/MR Compared with Contrast-Enhanced PET/CT for PET-Positive Lesions , 2014, Nuclear Medicine and Molecular Imaging.

[38]  Raymond R Tubbs,et al.  Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR , 2006, The American journal of surgical pathology.